None listed
Conditions
Brief summary
This study aims to evaluate the changes in lung function caused by the use of continuous positive airway pressure compared to standard therapy in patients who have been diagnosed with a worsening of their heart failure. Continuous positive airway pressure is a way of delivering pressure to the airway through a mask connected to a machine. It is used routinely in the treatment of heart failure to improve outcomes but how it works on the lungs is not well understood. By using a method of measuring lung function that can be done whilst on continuous positive airway pressure and that requires minimal active patient co-operation this trial hopes to provide insight into the mechanisms of this treatment.
Interventions
continuous positive airway pressure via nasal or full face mask at 10cm H2O pressure for 30 minutes from time of randomisation
continuous positive airway therapy via nasal or full face mask at a starting pressure of 4cm H2O increasing by 2cm H2O every 5 minutes for a total of 30 minutes from time of randomisation
Sponsors
Professor Matthew Naughton
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients diagnosed with an acute exacerbation of their heart failure Previous diagnosis of heart failure based on echocardiography Stable clincial status: respiratory rate <35 bpm, oxygen saturation via pulse oximeter(SpO2) > or equal to 85% on room air, systolic blood pressure > 90mmHg, clinically well perfused and able to speak in sentences Co-operative and able to give consent
Exclusion criteria
Pregnancy History of lung disease requireing treatment > 4 weeks Severe renal (requiring dialysis) or neurological disease Recent myocardial infarction (<6 weeks) Requiring itravenous inotropes
Outcome results
None listed